Spyre Therapeutics Inc (SYRE)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more
Ask ADVFN Intelligence (AI)
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -10.35 | -26.6409266409 | 38.85 | 40.26 | 27.9 | 661511 | 34.43064628 | CS |
| 4 | -4.17 | -12.7640036731 | 32.67 | 40.26 | 27.9 | 456032 | 34.9273442 | CS |
| 12 | 2.63 | 10.1662156939 | 25.87 | 40.26 | 25.15 | 505240 | 30.92003738 | CS |
| 26 | -9.02 | -24.0405117271 | 37.52 | 40.26 | 22.19 | 526648 | 29.33967887 | CS |
| 52 | 17.69 | 163.644773358 | 10.81 | 47.97 | 10.42 | 453399 | 30.14368401 | CS |
| 156 | 17.69 | 163.644773358 | 10.81 | 47.97 | 10.42 | 453399 | 30.14368401 | CS |
| 260 | 17.69 | 163.644773358 | 10.81 | 47.97 | 10.42 | 453399 | 30.14368401 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
